{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:39:48Z","timestamp":1791999588651,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xinjiang HIV\/AIDS Prevention and Control Research Key Laboratory","award":["XJYS1706"],"award-info":[{"award-number":["XJYS1706"]}]},{"DOI":"10.13039\/501100015925","name":"National Key Transform Program","doi-asserted-by":"publisher","award":["2018ZX10715-007"],"award-info":[{"award-number":["2018ZX10715-007"]}],"id":[{"id":"10.13039\/501100015925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This 12-year cohort study of 80 long-term non-progressors (LTNPs) observed a cumulative follow-up duration of 628.5 person-years. Among them, 60 received antiretroviral therapy (ART) for a total of 418.6 person-years. Twenty-four deaths occurred during the follow-up period, with an average age of 42.36\u00a0years and a lowest 8-year survival rate of 0.90. Cox model analysis revealed that the risk of AIDS-related death was 1.47 times higher for non-marital, non-commercial heterosexual transmission than for injection drug use. Treatment initiation at ages 31\u201340 was correlated with an elevated risk of mortality, while treatment for 3\u201310\u00a0years reduced mortality risks in untreated LTNPs. Flow cytometry observed significant differences in the proportion of NK cells. Long-term ART (&gt;\u20092\u00a0years) before LTNPs developed AIDS symptoms could lower mortality risk and potentially extend lifespan, especially when it was initiated at a younger age without affecting NK cell balance. Epidemiological and immunological studies on ART-treated LTNPs are vital for advancing HIV treatment and achieving functional cures for AIDS individuals.<\/jats:p>","DOI":"10.1007\/s10461-024-04396-x","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:01:32Z","timestamp":1718236892000},"page":"3151-3160","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Survival Analysis and Immune Differences of HIV Long-Term Non-progressors in Xinjiang China: A 12-Year Prospective Cohort Observation"],"prefix":"10.1007","volume":"28","author":[{"given":"Yuefei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkang","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0275-7914","authenticated-orcid":false,"given":"Mingjian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"key":"4396_CR1","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1097\/QAD.0000000000000049","volume":"28","author":"D Gurdasani","year":"2014","unstructured":"Gurdasani D, Iles L, Dillon DG, Young EH, Olson AD, Naranbhai V. A systematic review of definitions of extreme phenotypes of HIV control and progression. AIDS Lond Engl. 2014;28:149\u201362.","journal-title":"AIDS Lond Engl"},{"key":"4396_CR2","first-page":"311","volume":"8","author":"CA Sabin","year":"2013","unstructured":"Sabin CA, Lundgren JD. The natural history of HIV infection. Curr Opin HIV AIDS. 2013;8:311\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"4396_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1099\/vir.0.027102-0","volume":"92","author":"K Poropatich","year":"2011","unstructured":"Poropatich K, Sullivan DJ. Human immunodeficiency virus type 1 long-term non-progressors: the viral, genetic and immunological basis for disease non-progression. J Gen Virol. 2011;92:247\u201368.","journal-title":"J Gen Virol"},{"key":"4396_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/COH.0b013e328345a328","volume":"6","author":"B Autran","year":"2011","unstructured":"Autran B, Descours B, Avettand-Fenoel V, Rouzioux C. Elite controllers as a model of functional cure. Curr Opin HIV AIDS. 2011;6:181\u20137.","journal-title":"Curr Opin HIV AIDS"},{"key":"4396_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.20411\/pai.v5i1.364","volume":"5","author":"E Ruiz-Mateos","year":"2020","unstructured":"Ruiz-Mateos E, Poveda E, Lederman MM. Antiretroviral treatment for HIV elite controllers? Pathog Immun. 2020;5:121\u201333.","journal-title":"Pathog Immun"},{"key":"4396_CR6","unstructured":"Global HIV & AIDS statistics\u2014Fact sheet | UNAIDS [Internet]. 2022 [cited 2022 Sep 26]. Available from: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"4396_CR7","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/ni0505-430","volume":"6","author":"LJ Picker","year":"2005","unstructured":"Picker LJ, Watkins DI. HIV pathogenesis: the first cut is the deepest. Nat Immunol. 2005;6:430\u20132.","journal-title":"Nat Immunol"},{"key":"4396_CR8","unstructured":"Sg D, Sr L, Dv H. The end of AIDS: HIV infection as a chronic disease. Lancet Lond Engl. 2013 [cited 2022 Sep 30];382. Available from: http:\/\/210.26.175.175:8088\/ssnpp\/nb2hi4dthixs64dvmjwwkzbonzrwe2jonzwg2ltonfuc4z3poy9\/24152939\/."},{"key":"4396_CR9","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1097\/QAD.0000000000001050","volume":"30","author":"A Leon","year":"2016","unstructured":"Leon A, Perez I, Ruiz-Mateos E, Benito JM, Leal M, Lopez-Galindez C. Rate and predictors of progression in elite and viremic HIV-1 controllers. AIDS Lond Engl. 2016;30:1209\u201320.","journal-title":"AIDS Lond Engl"},{"key":"4396_CR10","doi-asserted-by":"publisher","first-page":"e01436","DOI":"10.1128\/JVI.01436-18","volume":"93","author":"M Ros\u00e1s-Umbert","year":"2019","unstructured":"Ros\u00e1s-Umbert M, Llano A, Bellido R, Olvera A, Ruiz-Riol M, Rocafort M. Mechanisms of abrupt loss of virus control in a cohort of previous HIV controllers. J Virol. 2019;93:e01436-e1518.","journal-title":"J Virol"},{"key":"4396_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25675","volume":"24","author":"M Borrell","year":"2021","unstructured":"Borrell M, Fern\u00e1ndez I, Etcheverrry F, Ugarte A, Plana M, Leal L. High rates of long-term progression in HIV-1-positive elite controllers. J Int AIDS Soc. 2021;24: e25675.","journal-title":"J Int AIDS Soc"},{"key":"4396_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/QAD.0000000000003072","volume":"36","author":"JB N\u2019takp\u00e9","year":"2022","unstructured":"N\u2019takp\u00e9 JB, Gabillard D, Moh R, Gardiennet E, Toni T, Kouame GM, et al. Elite and viremic HIV-1 controllers in West Africa. AIDS Lond Engl. 2022;36:29\u201338.","journal-title":"AIDS Lond Engl"},{"key":"4396_CR13","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s15010-020-01574-6","volume":"49","author":"T Engell-S\u00f8rensen","year":"2021","unstructured":"Engell-S\u00f8rensen T, Rieckmann A, Medina C, Silva T\u00e9 D, Rodrigues A, Fisker AB. Life expectancy of HIV-infected patients followed at the largest hospital in Guinea-Bissau is one-fourth of life expectancy of the background population. Infection. 2021;49:631\u201343.","journal-title":"Infection"},{"key":"4396_CR14","doi-asserted-by":"publisher","first-page":"S58","DOI":"10.1093\/infdis\/jiw258","volume":"214","author":"JC Mudd","year":"2016","unstructured":"Mudd JC, Brenchley JM. Gut mucosal barrier dysfunction, microbial dysbiosis, and their role in HIV-1 disease progression. J Infect Dis. 2016;214:S58.","journal-title":"J Infect Dis"},{"key":"4396_CR15","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/COH.0000000000000305","volume":"11","author":"KN Althoff","year":"2016","unstructured":"Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Curr Opin HIV AIDS. 2016;11:527.","journal-title":"Curr Opin HIV AIDS"},{"key":"4396_CR16","doi-asserted-by":"crossref","unstructured":"Li JZ, Blankson JN. How elite controllers and posttreatment controllers inform our search for an HIV-1 cure. J Clin Invest. 2021;131.","DOI":"10.1172\/JCI149414"},{"key":"4396_CR17","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1093\/infdis\/jis630","volume":"208","author":"H Hatano","year":"2013","unstructured":"Hatano H, Jain V, Hunt PW, Lee T-H, Sinclair E, Do TD, et al. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)\u2013expressing CD4+ T cells. J Infect Dis. 2013;208:50.","journal-title":"J Infect Dis"},{"key":"4396_CR18","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/imr.12065","volume":"254","author":"NR Klatt","year":"2013","unstructured":"Klatt NR, Chomont N, Douek DC, Deeks SG. Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunol Rev. 2013;254:326.","journal-title":"Immunol Rev"},{"key":"4396_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11904-017-0356-x","volume":"14","author":"CO Hileman","year":"2017","unstructured":"Hileman CO, Funderburg NT. Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV\/AIDS Rep. 2017;14:93.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"4396_CR20","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1056\/NEJM198906293202605","volume":"320","author":"CA Biron","year":"1989","unstructured":"Biron CA, Byron KS, Sullivan JL. Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med. 1989;320:1731\u20135.","journal-title":"N Engl J Med"},{"key":"4396_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1189\/jlb.0913514","volume":"96","author":"L Kuri-Cervantes","year":"2014","unstructured":"Kuri-Cervantes L, de Oca GS-M, Avila-R\u00edos S, Hern\u00e1ndez-Juan R, Reyes-Ter\u00e1n G. Activation of NK cells is associated with HIV-1 disease progression. J Leukoc Biol. 2014;96:7\u201316.","journal-title":"J Leukoc Biol"},{"issue":"189","key":"4396_CR22","first-page":"1491","volume":"2012","author":"GF Lichtfuss","year":"1950","unstructured":"Lichtfuss GF, Cheng W-J, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol Baltim Md. 1950;2012(189):1491\u20139.","journal-title":"J Immunol Baltim Md"},{"key":"4396_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bjhh.2017.02.007","volume":"39","author":"MP Colella","year":"2017","unstructured":"Colella MP, Santana BA, Conran N, Tomazini V, Costa FF, Calado RT. Telomere length correlates with disease severity and inflammation in sickle cell disease. Rev Bras Hematol E Hemoter. 2017;39:140\u20135.","journal-title":"Rev Bras Hematol E Hemoter"}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10461-024-04396-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-024-04396-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T08:18:02Z","timestamp":1726042682000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10461-024-04396-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":23,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["4396"],"URL":"https:\/\/doi.org\/10.1007\/s10461-024-04396-x","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]},"assertion":[{"value":"28 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee for AIDS Research at Xinjiang Medical University and the Xinjiang Uyghur Autonomous Region Center for Disease Control and Prevention. All patients provided informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}